{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:27:15Z","timestamp":1765232835151,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100020576","name":"Cancer Science Institute of Singapore, National University of Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020576","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["MOE2014- T3-1-006"],"award-info":[{"award-number":["MOE2014- T3-1-006"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clml.2019.12.024","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T02:29:12Z","timestamp":1578536952000},"page":"e165-e170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bacterial Infection Among Patients With Multiple Myeloma Treated With Bortezomib-based Induction Therapy: Real-World Experience in an Asian Cancer Center"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-8872","authenticated-orcid":false,"given":"Cinnie Yentia","family":"Soekojo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2082-0455","authenticated-orcid":false,"given":"Jia Zhen","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaslyn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-0655","authenticated-orcid":false,"given":"Melissa","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"De Mel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-8335","authenticated-orcid":false,"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.12.024_bib1","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.024_bib2","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.024_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0002-9343(81)90303-X","article-title":"Influence of treatment and response status on infection risk in multiple myeloma","volume":"71","author":"Perri","year":"1981","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2019.12.024_bib4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"Vesole","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.12.024_bib5","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"TEAMM Trial Management Group and Trial Investigators. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.12.024_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ijid.2007.02.002","article-title":"Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia","volume":"11","author":"Baskaran","year":"2007","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clml.2019.12.024_bib7","first-page":"526","article-title":"Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy","volume":"103","author":"Chen","year":"2004","journal-title":"J\u00a0Formos Med Assoc"},{"key":"10.1016\/j.clml.2019.12.024_bib8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0929-6646(10)60102-7","article-title":"Fluoroquinolone prophylaxis against febrile neutropenia in areas with high fluoroquinolone resistance--an Asian perspective","volume":"109","author":"Ng","year":"2010","journal-title":"J\u00a0Formos Med Assoc"},{"key":"10.1016\/j.clml.2019.12.024_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jac\/dkl199","article-title":"In\u00a0vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)","volume":"58","author":"Rossi","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.clml.2019.12.024_bib10","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3201\/eid1312.070299","article-title":"Antimicrobial drug resistance in Singapore hospitals","volume":"13","author":"Hsu","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.clml.2019.12.024_bib11","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.024_bib12","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.024_bib13","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2019.12.024_bib14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2146\/ajhp140194","article-title":"Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review","volume":"72","author":"Pherwani","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clml.2019.12.024_bib15","first-page":"2937","article-title":"A\u00a0novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) clinic","volume":"26","author":"Cooksley","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2019.12.024_bib16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1600-0609.2012.01814.x","article-title":"Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations","volume":"89","author":"Caravita","year":"2012","journal-title":"Eur J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:22Z","timestamp":1761870802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020300094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S2152265020300094"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.024","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacterial Infection Among Patients With Multiple Myeloma Treated With Bortezomib-based Induction Therapy: Real-World Experience in an Asian Cancer Center","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}